AUS
NZ
UK
CA
USA
IND
Highlights:
Polynovo (ASX:PNV) announces strong unaudited FY25 update
Sales momentum continues across US and global markets
Operating cash flow and product expansion boost company outlook
Polynovo (ASX:PNV), a health sector constituent of the ASX 200, is drawing attention in the asx newsletter after releasing its unaudited full-year FY25 update. The company’s performance update, shared after market hours, has sparked renewed interest in its shares during Wednesday’s trading session.
The company develops NovoSorb BTM, a dermal regeneration product used in surgical, traumatic, and burn-related skin injuries. The update highlights momentum in global sales, supported by continued product adoption in key regions.
Positive Momentum in Sales Across Global Markets
Polynovo reported robust growth in sales across its key operating geographies, including the United States and regions classified as Rest of the World. The company’s NovoSorb platform continues to gain recognition within the surgical and wound care space, contributing to commercial expansion.
In addition to the core NovoSorb BTM product, the company is developing new variants like NovoSorb MTX. These are aligned with Polynovo’s strategic focus on geographic diversification and clinical innovation, supporting its broader growth plans across hospitals and healthcare systems.
Operational Cash Flow and Expansion Strategy
The FY25 update also included encouraging details on cash flow performance. The business achieved a solid turnaround in operating cash flow in the latter half of the fiscal year, reinforcing its financial health.
This improved performance came alongside strategic expenditures, including capital investments and debt repayment. At the end of the period, the company reported a higher cash position, reflecting disciplined capital management and business execution.
Product Portfolio and Market Reach Continue to Grow
Polynovo confirmed that its technology is now supplied to hospitals in numerous countries, with its presence expanding globally. The company is actively supporting this growth through recruitment in key markets such as the United States, where it is building out its field force to support increasing demand for NovoSorb products.
The expansion strategy is further bolstered by new regulatory filings, aimed at unlocking additional markets and clinical use cases. The demand from surgeons and hospitals continues to evolve, with product applications extending beyond initial expectations.
Profitability Trajectory and Outlook
The company's financial update also pointed to a continued rise in operating earnings, supporting confidence in its trajectory into FY26. Profit momentum is building across major markets, including Australia, New Zealand, the UK, and the US.
Polynovo anticipates sustained revenue growth in the year ahead, supported by increased staffing and product uptake. Commercial sales and unit volumes have maintained upward movement through June, contributing to record-breaking monthly figures.
Frequently Asked Questions
- What does Polynovo (ASX:PNV) produce?
Polynovo develops NovoSorb BTM and MTX, medical devices used in dermal regeneration after surgery or injury. - Where is Polynovo seeing growth?
The company reports growth in the US, UK, Australia, and various Rest of World markets, with increased hospital adoption. - Is Polynovo expanding its product applications?
Yes, the company is broadening clinical applications and geographic reach through new regulatory filings and strategic hiring.
